CN1291738C - Anti-phlogistic anti-viral medicine compositon and technique for preparing the same - Google Patents
Anti-phlogistic anti-viral medicine compositon and technique for preparing the same Download PDFInfo
- Publication number
- CN1291738C CN1291738C CN 200510041462 CN200510041462A CN1291738C CN 1291738 C CN1291738 C CN 1291738C CN 200510041462 CN200510041462 CN 200510041462 CN 200510041462 A CN200510041462 A CN 200510041462A CN 1291738 C CN1291738 C CN 1291738C
- Authority
- CN
- China
- Prior art keywords
- ethanol
- chinese medicine
- injection
- extracting solution
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a traditional Chinese medicine for resisting inflammation and viruses and a preparation process thereof. The traditional Chinese medicine is prepared from raw materials according to the proportion by weight: 9 to 20 shares of spica prunellae, 15 to 30 shares of philippine violet herb and 15 to 25 shares of heartleaf houttuynia herb. The preparation process comprises the following steps that three kinds of medicinal materials are weighed according to a prescription and are processed through water extraction, alcohol deposition and purification or concentration by adding appropriate auxiliary materials. The traditional Chinese medicine has the effects of clearing heat and fire, and resisting inflammation, bacterium and viruses. The present invention has good effects of treating upper and lower respiratory tract infection and has the advantages of simple preparation process and low cost.
Description
Technical field
The invention belongs to field of traditional Chinese medicine pharmacy, relate to a kind of anti-phlogistic anti-viral medicine compositon, the invention still further relates to this preparation of drug combination technology.
Background technology
Spica Prunellae is inflorescence, fruit ear and the herb of Labiatae Prunella plant Spica Prunellae.The bitter in the mouth suffering, cold in nature.Function is liver heat removing and eyesight improving, mass dissipating and swelling eliminating.Cure mainly diseases such as headache is dizzy, conjunctival congestion and swelling pain, scrofula goiter.Herb contains triterpenoid saponin, and its glycoside unit is an oleanolic acid, also contains free oleanolic acid, ursolic acid, globulariacitrin, hyperin, suitable caffeic acid, anti-caffeic acid, tannin, volatile oil, a small amount of alkaloid and water soluble salt (being mainly potassium chloride).Contain anthocyanin, d-Camphora, d-Fructus Foeniculi mattress ketone musk of delphinidin and cyanidin etc. in the spica.Confirm that through zoopery this product has certain antitumor action, in addition, this product decoct all has stronger inhibitory action to ten various bacteria.
Herba Violae (Philippine Violet Herb), another name arrow grass, the tiger of walking alone, Cornu Caprae seu Ovis, rice cloth bag.Nature and flavor: bitter, hot, cold, nontoxic.The Herba Violae herb contains the esters of glycoside, flavonoid, wax, cerinic acid (Cerotic acid) and unsaturated acids etc.Cure mainly and control furuncle, carbuncle, scrofula, jaundice, dysentery, diarrhoea, conjunctival congestion, sore throat, venom.Join Herba Taraxaci, heat-clearing and toxic substances removing, mass dissipating and swelling eliminating strength strengthens; Join Flos Lonicerae, the detoxifcation removing heat from blood, the merit of detumescence heat radiation strengthens.
Herba Houttuyniae, is slightly cold at the nature and flavor suffering, returns lung meridian, and heat-clearing and toxic substances removing, detumescence, diuretic effect are arranged.Join Rhizoma Phragmitis, Radix Platycodonis, Fructus Trichosanthis etc. and can control lung abscess (lung abscess); Join Radix Scutellariae, Bulbus Fritillariae Uninbracteatae etc. and can treat the cough due to lung-heat; Join Flos Chrysanthemi Indici, Herba Taraxaci, Flos Lonicerae etc. and can control pathopyretic ulcer; Join Semen Plantaginis, Rhizoma Imperatae, Spora Lygodii etc. and can control damp and hot stranguria; Join Rhizoma Coptidis, the Radix Pulsatillae, the Radix Paeoniae Alba, Radix Scutellariae etc. and can control hygropyretic dysentery, also available bright product external application is in order to treatment pathopyretic ulcer disease.In addition, pharmacological research also shows, that this product has is antibacterial preferably, improve effects such as immunity, antiinflammatory, analgesia, hemostasis, antitussive, diuresis, even can prevent gastric cancer and pulmonary carcinoma.Document shows that (king likes flat Wang Chunhua, Herba Houttuyniae injectio treatment acute upper respiratory tract infection 32 routine observation of curative effect, the 3rd the 6th phase of volume of Traditional Chinese Medicine magazine): Herba Houttuyniae injectio is fresh Herba Houttuyniae distillate, and main effective ingredient is volatile oil (every 1ml injection is equivalent to fresh Herba Houttuyniae 2g) such as decanoylacetaldehyde, methylnonanone, lauryl aldehyde.Effect with heat clearing away, detoxifcation, modern pharmacology studies show that, Herba Houttuyniae injectio has antiviral, antibiotic, anti-inflammatory and antalgic, cough-relieving and strengthens specificity and nonspecific immunity (promotes the peripheral leukocytes phagocytic function, immunoglobulin forms, strengthen the activity of cellular immunization, humoral immune reaction and natural killer cell, strengthen patient's blood and apoplexy due to phlegm lysozyme activity and serum and dissolve plain level) function, be a kind of ideal treating both the principal and secondary aspects of a disease Chinese medicine preparation.Be used for acute upper respiratory tract infection, better through clinical observation result, clinical applying.
At present, the antiinflammatory anti virus herb of Cai Yonging has a variety ofly clinically, but yet there are no Spica Prunellae, Herba Violae, Herba Houttuyniae compatibility is used for the antiviral Chinese medicine composition of antiinflammatory.
Summary of the invention
The purpose of this invention is to provide the antiviral Chinese medicine composition of a kind of antiinflammatory.
Another object of the present invention provides the preparation technology of aforementioned pharmaceutical compositions.
Technical scheme of the present invention is the principle according to motherland's medical science, Spica Prunellae relieves inflammation or internal heat and makes eye bright, mass dissipating and swelling eliminating, Herba Houttuyniae heat-clearing and toxic substances removing, eliminating carbuncle evacuation of pus, Herba Violae heat-clearing and toxic substances removing, removing heat from blood detumescence, three medicines share, and have heat-clearing and fire-dispersing, antiinflammatory, antibiotic, antiviral effect, are used for the treatment of upper and lower respiratory tract infection and have good effect.
The objective of the invention is to realize by following measures:
The antiviral Chinese medicine of a kind of antiinflammatory, it is to be prepared from by following bulk drugs:
9～20 parts of Spica Prunellaes, 15～30 parts of Herba Violaes, 15～25 parts of Herba Houttuyniae.
Described Chinese medicine, its medicament are the dosage forms that allows on any pharmaceutics.
Described Chinese medicine, its dosage form are injection, oral liquid, pill, tablet, powder, granule, capsule, microcapsule or drop pill.
The preparation technology of described Chinese medicine comprises the following step:
A. water is carried: take by weighing three flavor medical materials by prescription, decoct with water 2～3 times, and each 1～2h, collecting decoction filters, and it is 1.05～1.15 that filtrate is concentrated into 60 ℃ of heat survey relative densities;
B. precipitate with ethanol: add ethanol and make and contain the alcohol amount and reach 60～80%, leave standstill, cold preservation 24～72h, filter filtrate recycling ethanol; With method precipitate with ethanol operation 1～2 time, must reclaim the extracting solution behind the ethanol;
The extracting solution purification that c. will reclaim behind the ethanol gets pre-mixing liquor, adds acceptable accessories, and technology is made required dosage form routinely, perhaps
D. fetch the extracting solution of receiving behind the ethanol and be condensed into 60～80 ℃ of heat to survey relative densities be 1.05～1.30 extractum, add acceptable accessories, technology is made required dosage form routinely.
The preparation technology of described Chinese medicine, the purifying process among the step c is with Hollow Fiber Ultrafiltration post ultrafiltration on the extracting solution, gets the molecular retention amount less than 10000 filtrate, pre-mixing liquor; Perhaps with polyamide column on the extracting solution with 60～95% ethanol elution, collect eluent, reclaim ethanol, pre-mixing liquor; It is an amount of perhaps extracting solution to be added 4% aqueous gelatin solution, leaves standstill, and adds ethanol and makes and contain the alcohol amount and reach 60～80%, and cold preservation is filtered, filtrate recycling ethanol, pre-mixing liquor.
The Hollow Fiber Ultrafiltration post is by selecting the fibrous membrane of certain molecular weight size for use, to reach removal all impurity greater than this molecular weight, keeping the effective ingredient less than this molecular weight.
Beneficial effect of the present invention:
One, experiment reagent:
5% glucose injection, FUFANG DANSHEN ZHUSHEYE, vitamin C injection, normal saline.
Two, laboratory animal:
Mice, rat, rabbit.
Three, experimental technique and result:
1, this injection (pressing embodiment 1 preparation) antiinflammatory action
1.1 to the bullate influence of mice auricular concha caused by dimethylbenzene xylene:
Get 30 of mices, health, body weight 20 ± 2g, the male and female dual-purpose divides 3 groups at random, and 10 every group, this injection of administration group tail vein injection 5.2ml/kg.Positive controls tail vein injection FUFANG DANSHEN ZHUSHEYE 1.3ml/kg vitaminize C injection 2.6ml/kg, blank group tail vein injection 5% glucose injection 5.2ml/kg, administration 5d.Behind the last administration 30min, dimethylbenzene 0.03ml is evenly dripped on the auris dextra shell, left auricular concha drips the distilled water contrast of equivalent.Put to death mice behind the 40min, take off auricle at ears symmetry place with the card punch of diameter 8mm. weigh with analytical balance, about two auricle weight differences be the swelling degree.The results are shown in Table 1.
Table 1 medicine of the present invention is to the influence of mice auricular concha swelling
| Group | Number of animals (only) | Mus ear swelling degree (mg x ± s) | Inhibitory rate of intumesce (%) |
| Blank group positive controls administration group | 10 10 10 | 9.8±1.7 9.5±2.6 7.0±2.6 * △ | 3.1 28.6 |
With blank group ratio,
*P＜0.05; Compare △ P＜0.01 with positive controls
1.2 to bring out the influence of rat paw inflammation by Ovum Gallus domesticus album:
Get 30 of rats, health, body weight 140 ± 10g, male and female dual-purpose.Divide 3 groups at random, 10 every group.This injection of administration group tail vein injection 3.6ml/kg; Positive controls tail vein injection FUFANG DANSHEN ZHUSHEYE 0.9ml/kg vitaminize C injection 1.8ml/kg, blank group tail vein injection 5% glucose injection 3.6ml/kg.Administration 5d, behind the last administration 15min, irritate stomach feedwater 10ml, the fresh albumen 0.1ml of left sufficient plantar subcutaneous injection 10% behind rat immediately then, measure the thickness of the sufficient sole of the foot about rat respectively at 5min, 30min, 60min, 120min, 240min, 360min, with its difference is the swelling degree, the results are shown in Table 2.
Table 2 pair rat is by the influence of pedal swelling due to the Ovum Gallus domesticus album
| Group | Number of animals (only) | Rat paw edema degree (cm) (x ± s) | |||||
| 5min | 30min | 1h | 2h | 4h | 6h | ||
| Blank group positive controls administration group | 10 10 10 | 0.194±0.043 0.209±0.040 0.144±0.040 * △ | 0.315±0.039 0.312±0.109 0.228±0.040 * △ | 0.278±0.027 0.269±0.049 0.188±0.049 * △ | 0.251±0.041 0.223±0.075 0.162±0.044 * △ | 0.214±0.052 0.187±0.048 0.137±0.018 * △ | 0.158±0.034 0.132±0.043 0.101±0.018 * △ |
Administration group and blank group compare,
*P＜0.01; Compare △ P＜0.05 with positive controls
Above result shows that this injection xylol inducing mouse auricular concha acute inflammation has stronger inhibitory action; The rat paw inflammation that Ovum Gallus domesticus album is caused also all has very strong inhibitory action at the swelling degree of different time, and is better than contrasting medicine.
1.3 influence to cott on pellet-induced granuloma formation:
Get 40 of body weight 140-170g rats, male and female half and half are divided into 4 groups at random, make the granulation tissue hyperplasia model for behind the etherization one of the aseptic cotton balls of each embedding 20mg of rat groin.Each group is pressed body surface area and is calculated the influence of the dosage observation of rat to cott on pellet-induced granuloma formation.1 group is given this injection 5.2ml/kg, and 2 groups are given this injection 2.6ml/kg, injects 0.5% dexamethasone sodium phosphate 0.005ml/kg for 3 groups, give the equivalent normal saline for 4 groups, all the lumbar injection successive administration was 7 days, put to death rat in the 8th day, separate granulation tissue, put in 80 ℃ of baking boxs and weigh after dry 5 hours.As a result, 1,2,3 group all can be suppressed cott on pellet-induced granuloma formation, see Table 3.
This injection of table 3 is to the influence of rat granulation tissue hyperplasia
| Group | Number of animals (only) | Granuloma dry weight (mg) |
| 1 group 2 groups 3 groups 4 groups | 10 10 10 10 | 28.23±10.89 32.13±13.24 36.25±14.31 83.15±21.83 |
2, bacteriostatic test:
2.1 make positive skin infection and acute peritonitis pathological model: 12 rabbit are divided into experimental group and matched group at random.In the left side same position cropping of every rabbit, shave hair, cut the long osculum of about 1cm with scalpel, reach subcutaneously deeply, from 500,000,000/kg of the inside injection of wound staphylococcus aureus, form positive skin infection; Simultaneously, give every rabbit lumbar injection inoculation large intestine bar mattress K
883,000,000,000/kg, cause acute peritonitis disease model.Experimental group adopted ear vein to inject this injection in 3 days in advance, and every rabbit press 10ml/kg time, was total to administration 8 days every day respectively 1 time sooner or later, finished to stop in preceding 24 hours administration; Matched group is not given any medicine, respectively organizes difference.
This injection forms the result of the test such as the table 4 of positive skin infection to tame rabbit inoculation gold-coloured staphylococci.Inoculate after 3 days, inflammatory reactions such as red, swollen, hot, tenderness are arranged around the matched group rabbit wound skin.
This injection of table 4 exempts to test the influence of positive skin infection to family
| Group | n/p | Area (m festers 2) | ||
| Body surface (x ± s) | The Intradermal side (x ± s) | Musclar layer (x ± s) | ||
| The experimental group matched group is real: to E/C | 6 5 P | 0.573±0.033 1.899±0.389 ＜0.01 | 0.021±0.020 0.861±0.094 ＜0.01 | 0.017±0.009 1.093±0.103 ＜0.01 |
Catch and kill and observe rabbit abdominal cavity inoculation escherichia coli K
88Form the test of acute peritonitis disease, the results are shown in Table 5.
This injection of table 5 is exempted from the main pathological change of experimental peritonitis to family
| Content | Matched group | Experimental group | |||||||||
| 1 | 2 | 7 | 8 | 10 | 3 | 4 | 5 | 6 | 11 | 12 | |
| Microabscess under the purulent exudate liver tunicle of free property abscess liver surface between swollen being dispersed in property of the intestinal tube serosal surface microabscess intestinal tube hemorrhagic necrosis intestinal tube of stomach wall microabscess mural abscess intestinal tube serosal surface exudate intestinal tube serosal surface limitation small intestine | + + + + + + + - - | + + + + + - + + - | + + + + + - + + - | + + + + + - + + - | + + + + + + + - - | - - - - - - - - - | - - - - - - - - - | - - + - - - - - - | - - - + - - - - - | - - + - - - - - - | - - - - - - - - - |
Annotate: "+" expression has pathological change; The no pathology of "-" expression changes
2.2 bacteriostatic test in the body: 40 of mices, male and female half and half are divided into experimental group and matched group at random.Every mouse hypodermic inoculation 0.2ml dilution factor is 10
-3Cultivation bacterium liquid, inject this injection 1.0ml/ only to experimental mice simultaneously, control group mice intraperitoneal injection of saline 1.0ml/ only injected for 1 week every day each 1 time sooner or later continuously, observed its death, survival number, and carried out statistical data and handle.
That inoculates the Salmonella mouse protection test the results are shown in Table 6.
Table 6 inoculation Salmonella mouse protection test result
| Group | Mice (only) | Dead (only) | Mortality rate (%) | Survival (only) | Survival rate (%) |
| Experimental group matched group sum | 10 10 20 | 2 10 12 | 20 100 | 8 0 8 | 80 |
Difference is extremely remarkable
That inoculates the bacillus subtilis mouse protection test the results are shown in Table 7.
Table 7 inoculation bacillus subtilis mouse protection test result
| Group | Mice (only) | Dead (only) | Mortality rate (%) | Survival (only) | Survival rate (%) |
| Experimental group matched group sum | 10 10 20 | 1 10 11 | 10 100 | 9 0 9 | 90 |
Difference is extremely remarkable
The result shows, family exempts from after the body surface wound inoculates suppurative gold-coloured staphylococci, and no matter the part area that festers is body surface, Intradermal side, or Musclar layer, and experimental group all has utmost point significant difference (P＜0.01) than matched group; Family exempts from abdominal cavity inoculation escherichia coli K
88After, catched and killed observation abdominal viscera inflammatory activity on the 6th day, matched group can all form the acute festering type diffuse peritonitis in 6 days; Experimental group has only a little serous coat exudate and 1 formation to limit to the peritonitis all the other 3 no any pathological changes except that 2; This injection not only has stronger inhibitory action to the growth of Salmonella, bacillus subtilis, and experimental group all has utmost point significant difference (P＜0.01) than matched group, and can reduce mouse death rate, improves survival rate, and its therapeutical effect is arranged.
2.3, external bacteriostasis: adopting in vitro, the medicinal liquid dilution method carries out external bacteriostatic experiment.With broth bouillon this injection is diluted to 1: 2 ... 1: 16 ... 1: 256 (pressing the multiple dilution) as table 8 dilution factor.Behind autoclaving 30min, every pipe to be cooled adds the bacterium liquid that two oeses are cultivated 6h, behind the cultivation 24h, observes bacterial growth situation in each pipe in 37 ℃ of incubators, the results are shown in Table 8.Minimum inhibitory concentration (MIC): to golden Portugal bacterium is 0.032g/mL; To Diplococcus pneumoniae is 0.063g/mL; To Hemolytic streptococcus is 0.063g/mL; To hemophilus influenza is 0.13g/mL, is 0.25g/mL to escherichia coli.
The external bacteriostasis (test tube method) of this injection of table 8
| The medicinal liquid dilution factor | Liquor strength (g/ml) | Staphylococcus aureus | Diplococcus pneumoniae | Hemolytic streptococcus | Salmonella | Escherichia coli |
| 1∶256 1∶128 1∶64 1∶32 1∶16 1∶8 | 0.0078 0.0156 0.0312 0.0625 0.125 0.25 | ++ + 0 0 0 0 | ++ + + + 0 0 | ++ + + + 0 0 | ++ ++ ++ + 0 0 | +++ +++ ++ 0 0 0 |
" ++ " obviously a small amount of growth of growth "+" " 0 " is aseptic
3, antivirus test
3.1, (HSV-1, HSV-2) suppress experiment: after treating that the Vero cell grows up to monolayer, with HSV-1, HSV-2 is diluted to 10,100,1000 and 10,000 four TCID to this injection to the dilution herpes simplex virus type 1 of difference, 2 types
50The virus attack amount, with each TCID
50Virus inoculation 8 pipe, wherein 4 pipes are this injection group, 4 pipes are the virus control group, other establishes 4 pipes and makes the drug cell matched group.The virus control group is changed and is kept liquid, and this injection group and drug cell matched group all change the maximal non-toxic concentration liquid of this injection, and promptly concentration is 1000 μ g/ml medicinal liquids.Then with all one weeks of culture tube rotating and culturing, every day observed and recorded cytopathy friendship condition, when the virus control group occurs ++-+++time judged result.
3.2 different dilution injection are tested the inhibition of herpes simplex virus: after treating that the Vero cell grows up to monolayer, use 100TCID
50Each pipe of virus attack amount inoculation, this injection is diluted to 1000 μ g/ml, 500 μ g/ml, 250 μ g/ml, 125 μ g/ml and five concentration of 62.5 μ g/ml, each concentration is established 4 pipes and is made this injection group, 4 pipes are made the drug cell matched group, and other establishes 4 pipes and makes public virus control group, with all one weeks of culture tube rotating and culturing, every day observed and recorded cytopathy situation, when the virus control group occurs ++-+++time judged result.
This injection suppresses experimental results to different dilution factor RSV and shows: when the viral infection amount more than or equal to 100TCID
50The time, this injection group is compared with the virus control group, and there were significant differences for lesion degree.When the viral infection amount less than 100TCID
50The time, pathological changes that this injection is acellular occurs, and the virus control group then has 25% cell pathological changes (seeing Table 9) to occur.
This injection of table 9 suppresses experimental result to different dilution factor herpes simplex virus
| Viral infection amount (TCID 50) | This injection group | The virus control group | The drug cell matched group |
| ＞100 100 ＜100 | ++-+++ + - | +++-++++ ++-+++ + | - - - |
Annotate :-cell does not have pathological changes ,+25% cytopathy ++ 50% cytopathy, +++75% cytopathy, ++ ++ 100% cytopathy.
Different dilution injection show the inhibition experimental result of herpes simplex virus: this injection suppresses the TD of herpes simplex virus
0, IC
50, MTC and TI value be respectively 1000 μ g/ml, 500 μ g/ml, 250 μ g/ml and 4.Along with liquor strength descends, the effect that this injection suppresses herpes simplex virus weakens.Three concentration groups of the 1000 μ g/ml of this injection, 500 μ g/ml and 250 μ g/ml are compared with the virus control group, and there were significant differences for lesion degree.(seeing Table 10)
Different dilution the injection of table 10 are to the inhibition experimental result of herpes simplex virus
| This injection group | The virus control group | The drug cell matched group | |||||
| C (μ g/ml) positive rate | 1000 | 500 | 250 | 125 | 62.5 | ||
| ± | + | ++ | ++-+++ | ++-+++ | ++-+++ | - | |
This experiment shows: when the virus attack amount is 100TCID
50The time, this injection is controlled and can be protected 75% cell to exempt from virus attack; When the virus attack amount less than 100TCID
50The time, then can protect cell fully and pathological changes do not occur.And further study the TD that it suppresses herpes simplex virus
0, IC
50, MTC and TI value are respectively 1000 μ g/ml, 500 μ g/ml, 250 μ g/ml and 4.
The medicine of the present invention that experiment is adopted prepares according to embodiment 1, but is not limited only to injection, and other all embodiment all can draw above-mentioned experimental result.
The specific embodiment
The invention will be further elaborated by the following examples.
Raw medicinal material is pressed the calculating of 100g/ part among the embodiment.
Embodiment 1:
Prescription: 15 parts of Spica Prunellaes, 20 parts of Herba Violaes, 20 parts of Herba Houttuyniae.
Preparation technology: take by weighing three flavor medical materials by recipe quantity, decoct with water 3 times, each 1h, collecting decoction filters, and it is 1.10 (60 ℃ of heat are surveyed) that filtrate is concentrated into relative density, add ethanol and make and contain alcohol amount and reach 70%, leave standstill, cold preservation 36h filters, filtrate recycling ethanol adds ethanol again and makes and contain alcohol amount and reach 80%, leaves standstill, cold preservation 48h, filter, filtrate recycling ethanol, it is an amount of to add 4% aqueous gelatin solution, leave standstill, add ethanol and make and contain alcohol amount and reach 80%, cold preservation, filter, filtrate recycling ethanol gets pre-mixing liquor, add the injection water to 5000ml, adding concentration is 0.15% sodium sulfite, decolorizing with activated carbon, coarse filtration, fine straining, 5ml/ props up embedding, 1000 of injection are made in sterilization.
Embodiment 2:
Prescription: 15 parts of Spica Prunellaes, 20 parts of Herba Violaes, 20 parts of Herba Houttuyniae.
Preparation technology: take by weighing three flavor medical materials by recipe quantity, decoct with water 2 times, each 2h, collecting decoction filters, and it is 1.10 (60 ℃ of heat are surveyed) that filtrate is concentrated into relative density, add ethanol and make and contain alcohol amount and reach 60%, leave standstill, cold preservation 24h, filter, reclaim ethanol, polyamide column on the filtrate, the ethanol gradient elution with 60%, 80%, 95% is collected eluent, after reclaiming ethanol, pre-mixing liquor, add the injection water to 2000ml, add concentration again and be 0.3% vitamin C, decolorizing with activated carbon, coarse filtration, fine straining, 2ml/ props up embedding, 1000 of injection are made in sterilization.
Embodiment 3:
Prescription: 10 parts of Spica Prunellaes, 15 parts of Herba Violaes, 15 parts of Herba Houttuyniae.
Preparation technology: take by weighing three flavor medical materials by recipe quantity, decoct with water 2 times, each 1.5h, collecting decoction filters, it is 1.10 (60 ℃ of heat are surveyed) that filtrate is concentrated into relative density, add ethanol and make and contain alcohol amount and reach 60%, leave standstill, cold preservation 48h filters, filtrate recycling ethanol, the ultrafiltration of last Hollow Fiber Ultrafiltration post, earlier with the fibrous membrane elimination major part macromole impurity of 50000 molecular retention amounts, it is 1～50,000 impurity that the fibrous membrane of reuse 10000 molecular retention amounts is removed molecular weight, get molecular weight less than 10000 filtrate, pre-mixing liquor, add concentration again and be 0.2% sodium pyrosulfite, add the injection water to 10000ml, decolorizing with activated carbon, coarse filtration, fine straining, 10ml/ props up embedding, 1000 of injection are made in sterilization.
Embodiment 4
Get the pre-mixing liquor under 3 of example 1, example 2 or the examples, add concentration and be 0.1～0.3% sodium sulfite, add glucose or sodium chloride adjusting etc. and ooze, technology is made infusion solutions routinely, and specification is 100ml/ bottle, 250l/ bottle or 500ml/ bottle.
Embodiment 5
Get the pre-mixing liquor under 3 of example 1, example 2 or the examples, be routinely added to sucrose, sodium sulfite and benzoate, add the injection water again to 10000ml, technology is made 1000 of oral liquids routinely.
Embodiment 6
Prescription: 12 parts of Spica Prunellaes, 20 parts of Herba Violaes, 15 parts of Herba Houttuyniae.
Preparation technology: take by weighing three flavor medical materials by recipe quantity, decoct with water 3 times, each 2h, collecting decoction filters, and filtrate is concentrated into relative density and is about 1.15 (60 ℃ of heat are surveyed), adds ethanol and makes and contain the alcohol amount and reach 70%, leaves standstill, cold preservation 48h, filters, and reclaims ethanol; Fetching the extracting solution concentrating under reduced pressure of receiving behind the ethanol, to become relative density be 1.30 thick extractum (60 ℃ of heat are surveyed), is routinely added to dextrin, sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, and technology is made 1000 of capsules routinely.
Embodiment 7
Prescription: 12 parts of Spica Prunellaes, 20 parts of Herba Violaes, 15 parts of Herba Houttuyniae.
Preparation technology: take by weighing three flavor medical materials by recipe quantity, decoct with water 3 times, each 2h, collecting decoction filters, and filtrate is concentrated into relative density and is about 1.10 (60 ℃ of heat are surveyed), adds ethanol and makes and contain the alcohol amount and reach 70%, leaves standstill, cold preservation 48h, filters, and reclaims ethanol; Fetching the extracting solution concentrating under reduced pressure of receiving behind the ethanol, to become relative density be 1.15 extractum (60 ℃ of heat are surveyed), and it is an amount of to be routinely added to pregelatinized Starch, carboxymethyl starch sodium, hypromellose sodium, magnesium stearate, and technology is made 1000 in tablet routinely.
Embodiment 8
Prescription: 12 parts of Spica Prunellaes, 20 parts of Herba Violaes, 15 parts of Herba Houttuyniae.
Preparation technology: take by weighing three flavor medical materials by recipe quantity, decoct with water 2 times, each 2h, collecting decoction filters, and filtrate is concentrated into relative density and is about 1.05 (60 ℃ of heat are surveyed), adds ethanol and makes and contain the alcohol amount and reach 60%, leaves standstill, cold preservation 48h, filters filtrate recycling ethanol; Fetching the extracting solution concentrating under reduced pressure of receiving behind the ethanol, to become relative density be 1.25 extractum (60 ℃ of heat are surveyed), is routinely added to cane sugar powder, dextrin, and technology is made 1000 bags of granules routinely.
Claims (4)
1, the antiviral Chinese medicine composition of a kind of antiinflammatory is characterized in that raw material composition and the parts by weight of wherein making active ingredient are: 9～20 parts of Spica Prunellaes, 15～30 parts of Herba Violaes, 15～25 parts of Herba Houttuyniae.
2, Chinese medicine composition according to claim 1, the dosage form that it is characterized in that this Chinese medicine composition are injection, oral liquid, pill, tablet, powder, granule, capsule, microcapsule or drop pill.
3, the preparation technology of Chinese medicine composition as claimed in claim 1 is characterized in that it comprises the following step:
A. water is carried: take by weighing three flavor medical materials by prescription, decoct with water 2～3 times, and each 1～2h, collecting decoction filters, and it is 1.05～1.15 that filtrate is concentrated into 60 ℃ of heat survey relative densities;
B. precipitate with ethanol: add ethanol and make and contain the alcohol amount and reach 60～80%, leave standstill, cold preservation 24～72h, filter filtrate recycling ethanol; With method precipitate with ethanol operation 1～2 time, must reclaim the extracting solution behind the ethanol;
The extracting solution purification that c. will reclaim behind the ethanol gets pre-mixing liquor, adds acceptable accessories, and technology is made required dosage form routinely, perhaps
D. fetch the extracting solution of receiving behind the ethanol and be condensed into 60～80 ℃ of heat to survey relative densities be 1.05～1.30 extractum, add acceptable accessories, technology is made required dosage form routinely.
4, the preparation technology of Chinese medicine composition according to claim 3 is characterized in that purifying process among the step c for Hollow Fiber Ultrafiltration post ultrafiltration on the extracting solution, gets the molecular retention amount less than 10000 filtrate, pre-mixing liquor; Perhaps with polyamide column on the extracting solution with 60～95% ethanol elution, collect eluent, reclaim ethanol, pre-mixing liquor; It is an amount of perhaps extracting solution to be added 4% aqueous gelatin solution, leaves standstill, and adds ethanol and makes and contain the alcohol amount and reach 60～80%, and cold preservation is filtered, filtrate recycling ethanol, pre-mixing liquor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510041462 CN1291738C (en) | 2005-08-12 | 2005-08-12 | Anti-phlogistic anti-viral medicine compositon and technique for preparing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510041462 CN1291738C (en) | 2005-08-12 | 2005-08-12 | Anti-phlogistic anti-viral medicine compositon and technique for preparing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1733149A CN1733149A (en) | 2006-02-15 |
| CN1291738C true CN1291738C (en) | 2006-12-27 |
Family
ID=36075904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510041462 Expired - Fee Related CN1291738C (en) | 2005-08-12 | 2005-08-12 | Anti-phlogistic anti-viral medicine compositon and technique for preparing the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1291738C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104922310B (en) * | 2015-05-21 | 2019-10-25 | 广东轻工职业技术学院 | A kind of Chinese medicine composition of bacteria resistance function and the application in daily necessities |
-
2005
- 2005-08-12 CN CN 200510041462 patent/CN1291738C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1733149A (en) | 2006-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101293038B (en) | Gallbladder leaves extract, preparing method, its preparation and uses | |
| CN101361765B (en) | Anti-coxsackie and anti-herpesvirus extract of selaginella tamariscina and extraction technique and formulation thereof | |
| CN1730015A (en) | Honey suckle extract and its preparing process and application | |
| CN101032547A (en) | Anti-inflammatory and antivirotic medicine composition | |
| CN101700290B (en) | Pharmaceutical composition for preventing and treating warm-heat diseases of livestock and poultry and preparation method thereof | |
| CN102872015B (en) | Stephanotis total alkaloid extract as well as preparation method and application thereof | |
| CN1219545C (en) | Polygonum capitatum extract and medicinal composition preparation thereof | |
| CN1939414B (en) | Medicinal composition with antibacterial and anti-inflammation functions | |
| CN115105502B (en) | Application of compound containing stephania plant alkaloid in preparation of cat infectious peritonitis medicine | |
| CN1291738C (en) | Anti-phlogistic anti-viral medicine compositon and technique for preparing the same | |
| CN1775254A (en) | Medicinal preparation for treating deaf and preparing method | |
| CN1278709C (en) | Medicine for treating cold and its preparing process | |
| CN101554405A (en) | Selfheal, mulberry leaf and wild chrysanthemum dripping pills and preparation method thereof | |
| CN100384431C (en) | Traditional Chinese medicine compositions | |
| CN1876044A (en) | A Chinese medicinal composition for treating infant fever caused by exogenous pathogen and preparation method thereof | |
| CN1742926A (en) | Zuoci preparation for deaf and new preparing method thereof | |
| CN1785212A (en) | Novel cinobufogenin freeze-drying powder injection, its prepn. method and quality control method | |
| CN1686277A (en) | Medicine for treating child common cold and its preparation method | |
| CN100339126C (en) | Chinese traditional medicine for preventing and treating biliary tract inflammation and its preparation process | |
| CN1289110C (en) | Capsule preparation for treating gynecological diseases and preparation process thereof | |
| CN101934048B (en) | Traditional Chinese medicine compound preparation for treating respiratory disease and preparation method thereof | |
| CN106728195B (en) | Seven-ingredient scutellaria detoxification granule, preparation method thereof and product quality control method | |
| CN106619767A (en) | Medicine composition for treating dairy cow mastitis as well as preparation method and application thereof | |
| CN1895458A (en) | Compound Chinese-medicinal extract for treating gynaopathy and its preparation | |
| CN100361662C (en) | Preparation method of traditional Chinese medicine compositions formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061227 Termination date: 20110812 |